Delivery Systems for Peptide Drugs

  • S. S. Davis
  • Lisbeth Illum
  • E. Tomlinson

Part of the NATO ASI Series book series (NSSA, volume 125)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Spencer Emtage
    Pages 23-33
  3. Larry A. Sternson, Thomas R. Malefyt
    Pages 35-47
  4. Hans Bundgaard
    Pages 49-68
  5. Leslie Z. Benet, Robert A. Baughman Jr.
    Pages 79-86
  6. Claudia Bibus
    Pages 105-113
  7. F. G. Hutchinson, B. J. A. Furr
    Pages 115-123
  8. Lynda M. Sanders, Karen M. Vitale, Georgia I. Mc Rae, Peter B. Mishky
    Pages 125-137
  9. Karl-Erik Falk, Jan-Erik Löfroth
    Pages 153-158
  10. Hans P. Merkle, Reinhold Anders, Jürgen Sandow, Werner Schurr
    Pages 159-175
  11. Shozo Muranishi, Kanji Takada, Hiroshi Yoshikawa, Masahiro Murakami
    Pages 177-189
  12. John P. Longenecker
    Pages 211-220
  13. Kenneth S. E. Su, Kristina M. Campanale, Laurane G. Mendelsohn, Gail A. Kerchner, Christian L. Gries
    Pages 221-232
  14. Musetta Hanson, G. Gazdick, J. Cahill, M. Augustine
    Pages 233-242

About this book


Recent years have seen enormous advances in the field of protein and peptide engineering and a greater understanding in the way in which biological response modifiers function in the body. It is now possible through the use of recombinant DNA techniques, or by solid phase protein synthesis, to produce significant quantities of a wide variety of regulatory agents that are therapeutically applicable. The list of these response modifiers expands almost daily to include interferons, macrophage activation factors, neuropeptides and agents that may have potential in cardiovascular disease, inflammation, contraception etc. Prospects to use some of these materials in medicine have reached the stage where products have either been approved by regulatory authorities or are the subject of applications as investigatory drugs or as new therapeutic agents. In some uses the pertinent agent will be administered on an acute basis in the form of a simple injection, as, for example, the use of a tissue plasminogen activator for the treatment of coronary infarct. In other cases regulatory proteins and peptides are indicated for chronic therapy and here they will need to be administered by an appropriate delivery system. Unfortunately, the research on delivery systems for peptides and proteins has not kept pace with the rapid progress in biotechnology and, consequently, there are presently few systems that are entirely appropriate for the administration of macromolecular drugs according to complex dosage regimens, (eg intermittent and pulsed therapy). Furthermore essential pharmacokinetic and pharmacodynamic data may be missing.


absorption biotechnology cardiovascular disease drug drug delivery inflammation interferon life sciences neuropeptides protein research tissue

Editors and affiliations

  • S. S. Davis
    • 1
  • Lisbeth Illum
    • 2
  • E. Tomlinson
    • 3
  1. 1.University of NottinghamNottinghamEngland
  2. 2.The Royal Danish School of PharmacyCopenhagenDenmark
  3. 3.Ciba-Geigy PharmaceuticalsHorshamEngland

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag US 1986
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4757-9962-0
  • Online ISBN 978-1-4757-9960-6
  • About this book